BACKGROUND: Immunotherapies targeting cellular immunity are currently approved for treatment of @entity320 , @entity1358 , and @entity263 . Studies on the immunogenicity and immune responsiveness of @entity5 are limited, therefore, it remains unclear to what extent T-cell-based immunotherapy holds promise for pediatric @entity5 . PROCEDURE: A new @entity980 cell line (M3-9-M) was derived from an @entity2875 ( @entity2875 ) occurring in a C57BL/6 @entity19 transgenic for hepatocyte growth factor and heterozygous for mutated @entity899 . @entity5 and @entity3 derived from M3-9-M were studied for similarities to @entity1 @entity2875 , and for immunogenicity and immune responsiveness. RESULTS: Primary and @entity3 develop after orthotopic injection of M3-9-M into immunocompetent C57BL/6 @entity19 , which mirror @entity1 @entity2875 with regard to histology, gene expression, and metastatic behavior. Whole cell vaccination using irradiated M3-9-M cells or M3-9-M-pulsed dendritic cells (DC)-induced @entity5 -specific T-cell responses that prevent @entity5 growth following low-dose @entity5 injection, and slow @entity5 growth following higher doses. Administration of anti- @entity3783 moAbs to deplete @entity1961 (+) @entity3783 (+)FOXP3(+) regulatory T cells prior to @entity5 vaccination enhanced the potency of the @entity5 vaccine. Adoptive immunotherapy with M3-9-M primed T cells plus DC-based vaccination resulted in complete eradication of day 10 M3-9-M derived @entity5 . CONCLUSIONS: M3-9-M derived @entity19 @entity2875 is immunogenic and immunoresponsive; regulatory T cells contribute to immune evasion by @entity19 @entity980 . Adoptive immunotherapy with DC vaccination can eradicate low @entity5 burdens. Future work will seek to identify the @entity5 -associated antigens that mediate protective and therapeutic immunity in this model.

@entity19 XXXX is immunogenic and responsive to T-cell-based immunotherapy.

@entity1 :: ('9606', 'Species') :: ['human'] @entity263 :: ('MESH:D011471', 'Disease') :: ['prostate cancer'] @entity5 :: ('MESH:D009369', 'Disease') :: ['ERMS tumor', 'tumor', 'pediatric tumors', 'Primary tumors', 'tumors', 'solid tumors'] @entity19 :: ('10090', 'Species') :: ['mice', 'mouse', 'murine'] @entity899 :: ('22060(Tax:10090)', 'Gene') :: ['p53'] @entity3783 :: ('16184(Tax:10090)', 'Gene') :: ['CD25'] @entity1358 :: ('MESH:D002292', 'Disease') :: ['renal cell carcinoma'] @entity1961 :: ('12504(Tax:10090)', 'Gene') :: ['CD4'] @entity2875 :: ('MESH:D018233', 'Disease') :: ['embryonal rhabdomyosarcoma', 'ERMS'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases', 'metastatic tumors'] @entity980 :: ('MESH:D012208', 'Disease') :: ['rhabdomyosarcoma'] @entity320 :: ('MESH:D008545', 'Disease') :: ['melanoma']
@entity980 :: (MESH:D012208,Disease) :: ['rhabdomyosarcoma']
